前列地尔注射液对糖尿病肾病患者血浆纤维蛋白原的影响

Effect of prostaglandin E1 on the plasma fibrinogen level in the patients with diabetic nephropathy

目的观察前列地尔注射液对糖尿病肾病(DN)患者血浆纤维蛋白原的影响。方法选择28例确诊为2型糖尿病肾病患者,随机分为治疗组和非治疗组(各为14例),治疗组予前列地尔注射液10μg,每日1次,疗程2周,余两组治疗相同。分别于治疗前及2周后查两组血浆纤维蛋白原、血尿素氮、肌酐和尿蛋白定量。结果治疗组血浆纤维蛋白原治疗后较治疗前明显下降(P<0.05),非治疗组血浆纤维蛋白原治疗前后比较无统计学差异(P>0.05),治疗组血尿素氮和肌酐与非治疗组比较明显下降(P<0.05)。结论前列地尔注射液可能具有降低血浆纤维蛋白原浓度作用,从而发挥延缓糖尿病肾病进展的作用。

Aim To study the effect of prostaglandin E1 on the plasma fibrinogen level in the patients with diabetic nephropathy. Metheds 28 diabetic patients were randomly divided into control and treatment group, 14 patients for each group. The treated group was given prostaglandin E1 （ l0 μg · d^- 1 ） , totally for 2 weeks. The control group was treated by routine treatment. The plasma fibrinogen, BUN,Scr and urinary albumin were compared between two groups. Results The plasma fibrinogen was descended obviously after treat- ment in the treated group（ P 〈 0. 05 ）. There was no significant difference of the plasma fibrinogen in control group （ P 〉 0. 05 ）. The BUN and Scr were descended obviously in the treated group compared with that of the control group （ P 〈 0. 05 ）. Conclusion Prostaglandin E1 can relieve the plasma fibrinogen and suppress the progression of diabetic nephropathy.